Safety, served now

On-Demand Virtual Conversation

HFS Research has estimated that nearly 70% of healthcare and pharma executives expect COVID-19 to have a much bigger impact on the industry than the 2008 downturn. Bottom-line pressures are now even more acute with supply interruptions. While the global race for a COVID-19 vaccine is in full swing, other clinical trials are delayed and regulatory timelines for several drugs nearing a decision are getting pushed into the future. The emerging recessionary economy is also likely to impact consumers’ ability to pay for drugs. In addition, the pharma industry is battling with image issues.

Key takeaways:

Reduce regulatory spend while building a clear ROI driven medical safety strategy
Build a superior pharmacovigilance driven patient safety brand. Click here.
Explore AI & ML algorithms to address the need for greater flexibility in manufacturing
Review blockchain and IoT gateways for universal tracking product theft, spoilage and counterfeits. Click here.

Watch our virtual conversation and learn how the life sciences industry surviving and thriving in this new (ab)normal by building trust by investing in resilience and safety – not only medical safety but also brand safety and supply safety.

Speakers

Watch Webinar